Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05282043
Other study ID # PEPICov
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 4, 2022
Est. completion date April 30, 2023

Study information

Verified date May 2022
Source Istanbul Arel University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

When the literature search is conducted, it is seen that there are many studies examining the effects of COVID-19 disease on individuals in various disease groups (MS, stroke, Parkinson, COPD, asthma, etc.) and age groups (adult, geriatric, etc.). However, it has been determined that there is no study examining the impacts of this disease on functional capacity, physical activity, pulmonary function, emotional state, sleep, and quality of life in healthy young adults. This study will reveal whether COVID-19 disease causes an effect on the mentioned parameters in young adults. The aim of recent study is to investigate functional capacity, respiration, pain, depression, sleep and quality of life in young adults post COVID-19. For this purpose, participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods. The goals of recent work, - To determine whether COVID-19 disease causes a decrease in functional capacity and changes in respiratory parameters in young adults, as well as to determine whether there are effects such as pain, depression, decreased sleep and quality of life, - To determine whether there are significant changes in the values of the relevant outcome measurements in all the mentioned parameters, - As a result of these, to determine the effects of COVID-19 disease on these parameters in young adults with objective, measurable data and to guide researchers and clinicians who do/will conduct studies on the subject.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 94
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - volunteers who are aged between 18-45 years - cases, who were infected with COVID-19 and had at least 12 weeks after diagnosis - cases, who have no symptoms of COVID-19 such as fever, cough, ageusia, anosmia, diarrhea, arthralgia, myalgia, sore throat, headache, chest pain Exclusion Criteria: - those have any cardiac or pulmonary disease history - those have diagnoses of any psychological disease (major depression, anxiety disorder, etc.) - those have any neurological or orthopaedic disease which hinders participation in physical activity

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults
Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.

Locations

Country Name City State
Turkey Istanbul Arel University Istanbul Zeytinburnu

Sponsors (1)

Lead Sponsor Collaborator
Istanbul Arel University

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Lee CC, Wu HJ, Chiou WB. Reminders of COVID-19 social distancing can intensify physical pain. Br J Soc Psychol. 2022 Apr;61(2):587-598. doi: 10.1111/bjso.12498. Epub 2021 Sep 12. — View Citation

Tanriverdi A, Savci S, Kahraman BO, Ozpelit E. Extrapulmonary features of post-COVID-19 patients: muscle function, physical activity, mood, and sleep quality. Ir J Med Sci. 2021 Jun 2. doi: 10.1007/s11845-021-02667-3. [Epub ahead of print] — View Citation

Tuzun S, Keles A, Okutan D, Yildiran T, Palamar D. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. Eur J Phys Rehabil Med. 2021 Aug;57(4):653-662. doi: 10.23736/S1973-9087.20.06563-6. Epub 2021 Jan 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 6-minute walk test unit: meters up to 6 months
Secondary magnitude of muscle strength of upper and lower extremity unit: Newtons up to 6 months
Secondary value of O2 saturation unit: percent up to 6 months
Secondary Corbin's postural assessment This scale has a total score range between 0-18. Every subscore range refers to specific situations about posture. These are mentioned below:
0-4: Excellent 5-7: Very good 8-10: Good 11-13: Fair 14 or more: Poor
up to 6 months
Secondary spirometer testing FEV1, FVC, FEV1/FVC values up to 6 months
Secondary pressure pain threshold unit: Newtons/cm2 up to 6 months
Secondary pain intensity unit: millimeters (according to Visual Analog Scale) up to 6 months
Secondary dyspnea severity (according to Modified Borg Scale) This scale has a total score range between 0-10. Every subscore refers to specific situations about dyspnea. These are mentioned below: 0: No Exertion 0.5: Very very Slight
Very Slight
Slight
Moderate
Somewhat Severe
Severe 6
7: Very Severe 8 9: Very very Severe 10: Maximal
up to 6 months
Secondary leg fatigue (according to Modified Borg Scale) This scale has a total score range between 0-10. Every subscore refers to specific situations about leg fatigue. These are mentioned below: 0: No Exertion 0.5: Very very Slight
Very Slight
Slight
Moderate
Somewhat Severe
Severe 6
7: Very Severe 8 9: Very very Severe 10: Maximal
up to 6 months
Secondary general fatigue (according to Fatigue Severity Scale) This scale has a 9-item which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients. Its minimum value is 9 and the maximum is 63. The higher the score indicates more severe fatigue and more impact on the person's activities. up to 6 months
Secondary quality of life questionnaire (according to Short Form-36) This form contains 36 questions. There are 8 different parameters of the questionnaire. These are mentioned below:
Physical functioning
Role limitations due to physical health
Role limitations due to emotional problems
Energy/fatigue
Emotional well-being
Social functioning
Pain
General health Every parameter has an average score that ranges between 0-100. Higher score indicates better situations that are specific to every parameter.
up to 6 months
Secondary depression severity (according to Beck Depression Inventory) This inventory has a score range between 0-63. Certain score ranges refer to specific conditions. These are mentioned below: 1-10: normal 11-16: Mild mood disturbance 17-20: Borderline clinical depression 21-30: Moderate depression 31-40: Severe depression over 40: Extreme depression up to 6 months
Secondary physical activity level (according to International Physical Activity Questionnaire/short form) In this form, there are 4 different activities which have a certain MET level. The formule which is used for obtain a total score is presented below:
-MET level x minutes of activity x events per week
According to total score, a classification is established:
Inactive
No activity OR
Some activity but not enough to meet Categories 2 or 3. Minimally Active Any one of the following criterias
3 or more days of vigorous activity of at least 20 minutes per day
5 or more days of moderate intensity activity or walking of at least 30 minutes per day
5 or more days of any combination of walking, moderate-intensity or vigorous activities achieving a minimum of at least 600 MET-min/week.
HEPA active Any one of the following criterias
Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week
7 or more days of any combination of walking, moderate-intensity or vigorous activities achieving a minimum of at least 3000 MET-minutes/week
up to 6 months
Secondary quality of sleep (according to Pittsburgh Sleep Quality Index) This index has 7 components and overall scoring alters between 0-21 points. 0 point indicates no difficulty while 21 points indicate severe difficulties. up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04544605 - Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients
Completed NCT05447039 - Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough N/A
Completed NCT05225220 - Multimodal Investigation of Post COVID-19 in Females N/A
Recruiting NCT05175807 - A Telemedicine Brief Mindfulness Intervention in Post-COVID-19 N/A
Recruiting NCT05371925 - Endothelial Protection in Post COVID-19 Patients With Sulodexide Phase 3
Recruiting NCT05212467 - AIR-program and HUS Internet Therapy Compared to Treatment as Usual in Functional Disorders and Post Covid-19 Condition N/A
Completed NCT04574050 - SELF-BREATHE RCT for Chronic Breathlessness N/A
Active, not recruiting NCT05298878 - Virtual Physical Rehabilitation for Patients Living With Long COVID N/A